Management of Osteoporosis in Postmenopausal Breast Cancer Survivors
Jiang X., Schnatz P.F., Kagan R. (2017) Management of Osteoporosis in Postmenopausal Breast Cancer Survivors. In: Pal L., Sayegh R. (eds) Essentials of Menopause Management. Springer, Cham
Print ISBN 978-3-319-42449-1
Online ISBN 978-3-319-42451-4
A 55-year-old Caucasian postmenopausal woman with BMI of 22.5 kg/m2 presents to the clinic for follow-up to discuss the results of her recent dual-energy X-ray absorptiometry (DXA) bone mineral density (BMD) scan. She has a personal history of premenopausal early-stage hormone receptor-positive breast cancer at age 47 and a family history of parental hip fracture. Following her initial breast cancer treatment, she received tamoxifen for 5 years (Age 47–52) followed by anastrozole (an aromatase inhibitor) until the current time. The DXA scan reports T-scores of −1.8 at the total hip and −1.6 at the lumbar spine. What would be your preferred management?